{
    "clinical_study": {
        "@rank": "119270", 
        "arm_group": {
            "arm_group_label": "botulinum toxin Type A", 
            "arm_group_type": "Experimental", 
            "description": "20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1."
        }, 
        "brief_summary": {
            "textblock": "A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX\u00ae) in\n      Chinese patients with moderate to severe frown lines (Glabellar Rhytides)  previously\n      treated with facial laser resurfacing."
        }, 
        "brief_title": "Treatment With Botulinum Toxin Type A (BOTOX\u00ae) in Chinese Patients With Moderate to Severe Frown Lines", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glabellar Rhytides", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  moderate or severe frown lines\n\n          -  facial laser treatment between 4 to 8 weeks prior to Day 1\n\n        Exclusion Criteria:\n\n          -  previous use of botulinum toxin for any indication\n\n          -  diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis\n\n          -  microdermabrasion or superficial peels, permanent make-up to the brow and forehead\n             area within the last 3 months\n\n          -  facial cosmetic procedures within the last 6 Months\n\n          -  treatment to forehead, brow, nose or midface areas with any filler within the last 12\n             months\n\n          -  use of a new topical skin care product within 1 month of the screening\n\n          -  any prior forehead or periorbital surgery or brow lift\n\n          -  deep dermal scarring, excessively thick sebaceous skin, and/ or loss of skin\n             elasticity\n\n          -  any facial skin infection or unhealed skin lesion\n\n          -  pregnant or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814670", 
            "org_study_id": "AP-BTXC-12-001"
        }, 
        "intervention": {
            "arm_group_label": "botulinum toxin Type A", 
            "description": "20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.", 
            "intervention_name": "botulinum toxin Type A", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "onabotulinumtoxinA"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Investigator's Assessment of the Severity of Frown Lines at Maximum Contraction Using the 4-point Facial Wrinkle Scale", 
            "safety_issue": "No", 
            "time_frame": "Day 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigator's Assessment of the Severity of Frown Lines at Rest Using the 4-point Facial Wrinkle Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "measure": "Subject's Assessment of the Severity of Frown Lines at Maximum Contraction Using the 4-point Facial Wrinkle Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "measure": "Subject's Assessment of the Severity of Frown Lines at Rest Using the 4-point Facial Wrinkle Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}